Aristotle Fund Values Revolution Medicines Under 1x Peak Sales After Daraxonrasib Phase 3
Aristotle Growth Equity Fund named Revolution Medicines among its top five Q4 2025 holdings, highlighting phase 3 candidate Daraxonrasib for advanced NSCLC and PDAC. Daraxonrasib holds FDA Breakthrough Therapy Designation and could generate several billion dollars in PDAC revenue by the mid-2030s, valuing the company at under 1x peak sales.
1. Investor Letter Endorsement
In its fourth-quarter 2025 investor letter, Aristotle Growth Equity Fund named Revolution Medicines among its top five holdings, citing the company’s precision oncology pipeline as a catalyst for future performance.
2. Daraxonrasib Clinical Progress
Revolution Medicines’ lead candidate, Daraxonrasib (RMD-6236), is in phase 3 trials for advanced non-small cell lung cancer and pancreatic ductal adenocarcinoma, and has received FDA Breakthrough Therapy Designation plus inclusion in the National Priority Review Voucher program.
3. Valuation and Revenue Outlook
Sell-side analysts project Daraxonrasib could generate several billion dollars in PDAC revenue by the mid-2030s, implying a current valuation below 1x potential peak sales, lower than historical biotech M&A multiples.